Dear Friend,

This year Democracy Now! is celebrating our 25th anniversary—that's 25 years of bringing you fearless, independent reporting. Since our very first broadcast in 1996, Democracy Now! has refused to take government or corporate funding, because nothing is more important to us than our editorial independence. But that means we rely on you, our audience, for support. Please donate today in honor of our 25th anniversary and help us stay on air for another 25 years. We can't do our work without you. Right now, a generous donor will even DOUBLE your gift, which means it’ll go twice as far! This is a challenging time for us all, but if you're able to make a donation, please do so today. Thank you and remember, wearing a mask is an act of love.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.

Donate

European Union Officials Consider Use of Russian COVID-19 Vaccine

HeadlineApr 13, 2021

In Brussels, European Union officials are deciding whether to allow emergency use of Russia’s Sputnik V vaccine, after many European nations suspended use of AstraZeneca’s vaccine for younger people amid reports of rare incidents of blood clots. In clinical trials, the two-dose Sputnik V outperformed AstraZeneca with over 90% efficacy at preventing COVID-19.

Regeneron Pharmaceuticals has asked the U.S. Food and Drug Administration to expand emergency use of its monoclonal antibody cocktail. Regeneron says a clinical trial showed its drug reduced the risk of symptomatic infection by over 80% among people who lived in the same household as someone who tested positive for coronavirus.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation
Top